AI Article Synopsis
Article Abstract
Forty patients aged 65-80 with minor-medium signs of brain aging were treated for 6 months with daily 90 mg doses of nimodipine. Treatment was well tolerated in that the minor side effects reported by a few of the patients never required withdrawal of the drug. Treatment proved useful, as shown by a variety of mental tests, in 69.5% of cases. In 20% conditions remained unchanged and in 9.5% further deterioration was observed. The authors conclude that nimodipine may be considered a useful therapeutic resource for phenomena of brain aging.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Weight trajectories in aging humanized APOE mice with translational validity to human Alzheimer's risk population: A retrospective analysis.
PLoS One
January 2025
Center for Innovation in Brain Science, University of Arizona Health Sciences, Tucson, Arizona, United States of America.
Translational validity of mouse models of Alzheimer's disease (AD) is variable. Because change in weight is a well-documented precursor of AD, we investigated whether diversity of human AD risk weight phenotypes was evident in a longitudinally characterized cohort of 1,196 female and male humanized APOE (hAPOE) mice, monitored up to 28 months of age which is equivalent to 81 human years. Autoregressive Hidden Markov Model (AHMM) incorporating age, sex, and APOE genotype was employed to identify emergent weight trajectories and phenotypes.
View Article and Find Full Text PDFNOTCH3 Mutation Causes Glymphatic Impairment and Promotes Brain Senescence in CADASIL.
CNS Neurosci Ther
January 2025
Department of Neurology, Mental and Neurological Disease Research Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Aims: The aim of this study is to investigate the role of glymphatic function of cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL), the most common monogenic small vessel disease caused by NOTCH3 mutation, and to explore potential therapeutic strategies to improve glymphatic function.
Methods: We assessed glymphatic influx and efflux function in CADASIL mouse models (Notch3) and correlated these findings with brain atrophy in CADASIL patients. We also investigated the underlying mechanisms of glymphatic impairment, focusing the expression of AQP4 in astrocytic endfeet.
Computational simulation of cranial soft tissue expansion on the cranium during early postnatal growth in humans.
J Anat
January 2025
Department of Musculoskeletal & Ageing Science, Institute of Life Course & Medical Sciences (ILCaMS) and Human Anatomy Resource Centre (HARC), Education Directorate, University of Liverpool, Liverpool, UK.
The importance of interactions between neighbouring rapidly growing tissues of the head during development is recognised, yet this competition for space remains incompletely understood. The developing structures likely interact through a variety of mechanisms, including directly genetically programmed growth, and are mediated via physiological signalling that can be triggered by structural interactions. In this study, we aimed to investigate a different but related potential mechanism, that of simple mechanical plastic deformation of neighbouring structures of the head in response to soft tissue expansion during human postnatal ontogeny.
View Article and Find Full Text PDFAge, cancer, and the dual burden of cancer and doxorubicin in skeletal muscle wasting in female rats: which one to blame?
Biogerontology
January 2025
UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116, Gandra, Portugal.
Sarcopenia and cancer cachexia are two life-threatening conditions often misdiagnosed. The skeletal muscle is one of the organs most adversely affected by these conditions, culminating in poor quality of life and premature mortality. In addition, it has been suggested that chemotherapeutic agents exacerbate cancer cachexia, as is the case of doxorubicin.
View Article and Find Full Text PDFFavorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.
J Neurol
January 2025
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Introduction: The large-scale approval of anti-amyloid monoclonal antibodies for treating Alzheimer's disease (AD) has raised concerns about their safety due to treatment-emergent amyloid-related imaging abnormalities (ARIA).
Methods: We present two cases of patients diagnosed with mild cognitive impairment due to AD who were enrolled in the GRADUATE I clinical trial. They received subcutaneous gantenerumab every two weeks during the study period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!